Reforms and initiatives in Scotland in recent years to encourage the prescribing of generic drugs, their influence and implications for other countries

Brian Godman, Iain Bishop, Alexander E Finlayson, Stephen Campbell, Hye-Young Kwon, Marion Bennie

Research output: Contribution to journalArticle

62 Citations (Scopus)

Abstract

Scotland has introduced a number of initiatives to enhance the prescribing of low-cost generic drugs versus originators and patent products in a class where these are seen as similar. The objective of this review is to appraise the influence of the various measures on subsequent utilization patterns and expenditure in high-volume classes to provide guidance. This review is principally a narrative review of published studies. The authors' found supply-side measures resulted in generic prices as low as 3% of pre-patent loss prices. Multiple demand-side measures resulted in high international non-proprietary name prescribing, and a considerable increase in prescribing efficiency for the proton pump inhibitors, statins, renin-angiotensin inhibitor drugs and selective serotonin reuptake inhibitors. There were no specific activities encouraging the prescription of losartan versus other angiotensin receptor blockers or risperidone versus other atypical antipsychotic drugs following generics and no change in their utilization patterns post generics. The authors can conclude multiple measures are needed to change physician prescribing habits. Authorities cannot rely on any 'spillover' effects to affect future prescribing, even in closely related classes.

LanguageEnglish
Pages469-482
Number of pages14
JournalExpert Review of Pharmacoeconomics and Outcomes Research
Volume13
Issue number4
DOIs
Publication statusPublished - Aug 2013

Fingerprint

Generic Drugs
Scotland
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Risperidone
Losartan
Proton Pump Inhibitors
Angiotensin Receptor Antagonists
Angiotensins
Serotonin Uptake Inhibitors
Health Expenditures
Renin
Antipsychotic Agents
Habits
Names
Prescriptions
Physicians
Costs and Cost Analysis
Pharmaceutical Preparations

Keywords

  • attitude of health personnel
  • cost savings
  • cost-benefit analysis
  • drug costs
  • drug prescriptions
  • drugs, generic
  • guideline adherence
  • Health care reform
  • health expenditures
  • health knowledge, attitudes, practice
  • health policy
  • humans
  • physician incentive plans
  • physician's practice patterns
  • policy making
  • practice guidelines as topic
  • scotland

Cite this

@article{bda04070ea6f43e0bab5d843dfe561b3,
title = "Reforms and initiatives in Scotland in recent years to encourage the prescribing of generic drugs, their influence and implications for other countries",
abstract = "Scotland has introduced a number of initiatives to enhance the prescribing of low-cost generic drugs versus originators and patent products in a class where these are seen as similar. The objective of this review is to appraise the influence of the various measures on subsequent utilization patterns and expenditure in high-volume classes to provide guidance. This review is principally a narrative review of published studies. The authors' found supply-side measures resulted in generic prices as low as 3{\%} of pre-patent loss prices. Multiple demand-side measures resulted in high international non-proprietary name prescribing, and a considerable increase in prescribing efficiency for the proton pump inhibitors, statins, renin-angiotensin inhibitor drugs and selective serotonin reuptake inhibitors. There were no specific activities encouraging the prescription of losartan versus other angiotensin receptor blockers or risperidone versus other atypical antipsychotic drugs following generics and no change in their utilization patterns post generics. The authors can conclude multiple measures are needed to change physician prescribing habits. Authorities cannot rely on any 'spillover' effects to affect future prescribing, even in closely related classes.",
keywords = "attitude of health personnel, cost savings, cost-benefit analysis, drug costs, drug prescriptions, drugs, generic, guideline adherence, Health care reform, health expenditures, health knowledge, attitudes, practice, health policy, humans, physician incentive plans, physician's practice patterns, policy making, practice guidelines as topic, scotland",
author = "Brian Godman and Iain Bishop and Finlayson, {Alexander E} and Stephen Campbell and Hye-Young Kwon and Marion Bennie",
year = "2013",
month = "8",
doi = "10.1586/14737167.2013.820956",
language = "English",
volume = "13",
pages = "469--482",
journal = "Expert Review of Pharmacoeconomics and Outcomes Research",
issn = "1473-7167",
number = "4",

}

Reforms and initiatives in Scotland in recent years to encourage the prescribing of generic drugs, their influence and implications for other countries. / Godman, Brian; Bishop, Iain; Finlayson, Alexander E; Campbell, Stephen; Kwon, Hye-Young; Bennie, Marion.

In: Expert Review of Pharmacoeconomics and Outcomes Research, Vol. 13, No. 4, 08.2013, p. 469-482.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Reforms and initiatives in Scotland in recent years to encourage the prescribing of generic drugs, their influence and implications for other countries

AU - Godman, Brian

AU - Bishop, Iain

AU - Finlayson, Alexander E

AU - Campbell, Stephen

AU - Kwon, Hye-Young

AU - Bennie, Marion

PY - 2013/8

Y1 - 2013/8

N2 - Scotland has introduced a number of initiatives to enhance the prescribing of low-cost generic drugs versus originators and patent products in a class where these are seen as similar. The objective of this review is to appraise the influence of the various measures on subsequent utilization patterns and expenditure in high-volume classes to provide guidance. This review is principally a narrative review of published studies. The authors' found supply-side measures resulted in generic prices as low as 3% of pre-patent loss prices. Multiple demand-side measures resulted in high international non-proprietary name prescribing, and a considerable increase in prescribing efficiency for the proton pump inhibitors, statins, renin-angiotensin inhibitor drugs and selective serotonin reuptake inhibitors. There were no specific activities encouraging the prescription of losartan versus other angiotensin receptor blockers or risperidone versus other atypical antipsychotic drugs following generics and no change in their utilization patterns post generics. The authors can conclude multiple measures are needed to change physician prescribing habits. Authorities cannot rely on any 'spillover' effects to affect future prescribing, even in closely related classes.

AB - Scotland has introduced a number of initiatives to enhance the prescribing of low-cost generic drugs versus originators and patent products in a class where these are seen as similar. The objective of this review is to appraise the influence of the various measures on subsequent utilization patterns and expenditure in high-volume classes to provide guidance. This review is principally a narrative review of published studies. The authors' found supply-side measures resulted in generic prices as low as 3% of pre-patent loss prices. Multiple demand-side measures resulted in high international non-proprietary name prescribing, and a considerable increase in prescribing efficiency for the proton pump inhibitors, statins, renin-angiotensin inhibitor drugs and selective serotonin reuptake inhibitors. There were no specific activities encouraging the prescription of losartan versus other angiotensin receptor blockers or risperidone versus other atypical antipsychotic drugs following generics and no change in their utilization patterns post generics. The authors can conclude multiple measures are needed to change physician prescribing habits. Authorities cannot rely on any 'spillover' effects to affect future prescribing, even in closely related classes.

KW - attitude of health personnel

KW - cost savings

KW - cost-benefit analysis

KW - drug costs

KW - drug prescriptions

KW - drugs, generic

KW - guideline adherence

KW - Health care reform

KW - health expenditures

KW - health knowledge, attitudes, practice

KW - health policy

KW - humans

KW - physician incentive plans

KW - physician's practice patterns

KW - policy making

KW - practice guidelines as topic

KW - scotland

U2 - 10.1586/14737167.2013.820956

DO - 10.1586/14737167.2013.820956

M3 - Article

VL - 13

SP - 469

EP - 482

JO - Expert Review of Pharmacoeconomics and Outcomes Research

T2 - Expert Review of Pharmacoeconomics and Outcomes Research

JF - Expert Review of Pharmacoeconomics and Outcomes Research

SN - 1473-7167

IS - 4

ER -